Type 17 CD8+ T cells display enhanced antitumor immunity

AUTOR(ES)

Hinrichs, Christian S.

FONTE

American Society of Hematology

RESUMO

Interleukin-17 (IL-17)–secreting CD8+ T cells have been described, but they have not been thoroughly studied and they do not have a known role in cancer immunotherapy. We skewed CD8+ T cells to secrete IL-17 through priming in Th17-polarizing conditions. IL-17–producing CD8+ T cells demonstrated reduced expression of Eomes and diminished cytolytic differentiation in vitro. However, after adoptive transfer, these cells converted to interferon-γ–producing effector cells and mediated regression of large, established tumors. This improved antitumor immunity was associated with increased expression of IL-7R-alpha, decreased expression of killer cell lectin-like receptor G1, and enhanced persistence of the transferred cells. This report is the first description of a cancer therapy with IL-17–secreting CD8+ T cells. These findings have implications for the improvement of CD8+ T cell–based adoptive immunotherapy.

Documentos Relacionados

• Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells
• Protective cellular retroviral immunity requires both CD4+ and CD8+ immune T cells.
• IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells
• Role for CD8+ T cells in antichlamydial immunity defined by Chlamydia-specific T-lymphocyte clones.
• Immunity to Murine Chlamydia trachomatis Genital Tract Reinfection Involves B Cells and CD4+ T Cells but Not CD8+ T Cells